[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Niagen Bioscience Inc (NAGE)

Niagen Bioscience Inc (NAGE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Niagen Bioscience's Revenue Momentum Tells One Story, but Operating Profit Tells Another

Niagen Bioscience (NAGE) reports first-quarter 2026 earnings after market close on May 6, 2026, with analysts expecting continued profitability from the biotechnology company's NAD+ metabolism products. The central question is whether NAGE can sustain its remarkable streak of earnings beats—having exceeded estimates by 50% to 150% in each of the past four quarters—while navigating a technical backdrop that has turned increasingly bearish. With the stock trading at $4.82, well below its 100-day and 200-day moving averages, investors will scrutinize whether fundamental momentum can overcome deteriorating technical sentiment.

Niagen Bioscience operates as a clinical-stage biotechnology company focused on healthy aging products through NAD+ metabolism, commercializing...

Fundamentals

See More
  • Market Capitalization, $K 394,794
  • Shares Outstanding, K 80,080
  • Annual Sales, $ 129,420 K
  • Annual Income, $ 17,380 K
  • EBIT $ 14 M
  • EBITDA $ 15 M
  • 60-Month Beta 2.17
  • Price/Sales 3.00
  • Price/Cash Flow 23.92
  • Price/Book 5.06

Options Overview Details

View History
  • Implied Volatility 132.15% (+20.33%)
  • Historical Volatility 44.30%
  • IV Percentile 80%
  • IV Rank 10.74%
  • IV High 789.28% on 02/18/26
  • IV Low 53.07% on 06/27/25
  • Expected Move (DTE 10) 0.68 (14.11%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 245
  • Volume Avg (30-Day) 268
  • Put/Call OI Ratio 0.24
  • Today's Open Interest 11,269
  • Open Int (30-Day) 13,186
  • Expected Range 4.14 to 5.50

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $0.06
  • Number of Estimates 2
  • High Estimate $0.08
  • Low Estimate $0.04
  • Prior Year $0.04
  • Growth Rate Est. (year over year) +50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.36 +10.68%
on 04/10/26
5.12 -5.89%
on 05/04/26
+0.44 (+10.05%)
since 04/02/26
3-Month
4.16 +15.87%
on 03/30/26
5.78 -16.61%
on 03/05/26
-0.31 (-6.04%)
since 02/05/26
52-Week
4.16 +15.87%
on 03/30/26
14.69 -67.19%
on 06/30/25
-3.63 (-42.96%)
since 05/05/25

Most Recent Stories

More News
Niagen Bioscience's Revenue Momentum Tells One Story, but Operating Profit Tells Another

Barchart Research What to Expect from NAGE Earnings NAGE Generated May 5, 2026 Current Price $4.82 EPS Estimate $$0.06 Consensus Rating Strong Buy Average Move 20.64% Niagen Bioscience's Revenue Momentum...

NAGE : 4.82 (-2.23%)
Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering

New telehealth platform introduces prescription-only Niagen At-Home Injection Kit, expanding access to pharmaceutical-grade NAD+ support for cellular and tissue health delivered directly to eligible patients'...

NAGE : 4.82 (-2.23%)
Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plusâ„¢

Partnership unlocks Olympia’s established clinic network for Niagen Plus, expands pharmaceutical-grade Niagen supply chain, and brings liquid compounded vials to market

NAGE : 4.82 (-2.23%)
Niagen Bioscience to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that it will hold a conference...

NAGE : 4.82 (-2.23%)
Niagen Bioscience Collaborates with USP to Establish First-Ever USP Monograph for Nicotinamide Riboside Chloride (NRCl), the Patented Form in Niagen®

NR is the first among NR, NMN, and NAD+ to receive a pharmacopeial quality benchmark, reinforcing Niagen Bioscience’s leadership in NAD+ science and ingredient quality

NAGE : 4.82 (-2.23%)
Niagen Bioscience Announces First Cruise Ship Clinic Partnership with OneSpaWorld, Bringing the NAD-Boosting Benefits of Niagen IV to the High Seas

Niagen IV launches across Medi-Spa clinics on high-end cruise ships, expanding Niagen Plus’ footprint

OSW : 24.04 (+2.39%)
NAGE : 4.82 (-2.23%)
Niagen Bioscience Increases Share Repurchase Program to $20 Million

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Board of Directors...

NAGE : 4.82 (-2.23%)
Niagen Bioscience to Present at the 38th Annual ROTH Conference

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will...

NAGE : 4.82 (-2.23%)
Niagen Bioscience Surpasses 300 External Research Agreements from Leading Global Institutions on Niagen®, Contributing to 45 Published Clinical Studies

By supporting investigator-initiated research worldwide, the program has helped establish Niagen Bioscience as a foundational force in advancing NAD+ understanding across the industry

NAGE : 4.82 (-2.23%)
Niagen Bioscience Launches Niagen® Skincare Innovation Lab and Debuts Dermatologist-Tested Niagen NanoCloud™, From Tru Niagen Powered by Patented Niagen®

Launch expands Niagen ® into the growing skincare category through a limited-release model designed to generate consumer insights and inform future innovation

NAGE : 4.82 (-2.23%)

Business Summary

Niagen Bioscience Inc. is a nicotinamide adenine dinucleotide science and healthy-aging research company. Niagen Bioscience Inc., formerly known as ChromaDex Corp., is based in LOS ANGELES.

See More

Key Turning Points

3rd Resistance Point 5.21
2nd Resistance Point 5.11
1st Resistance Point 4.96
Last Price 4.82
1st Support Level 4.71
2nd Support Level 4.61
3rd Support Level 4.46

See More

52-Week High 14.69
Fibonacci 61.8% 10.67
Fibonacci 50% 9.42
Fibonacci 38.2% 8.18
Last Price 4.82
52-Week Low 4.16

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.